Core Viewpoint - In a slowing global beauty industry, Galderma, a skin-focused company, has achieved significant growth, with net sales surpassing $5 billion for the first time, reaching $5.207 billion (approximately 358.92 billion RMB), a year-on-year increase of 17.7% [3][4]. Financial Performance - Galderma's record financial performance in 2025 includes growth across all product categories and major regional markets, driven by a clear strategic positioning and a science-based innovation approach [4]. - The company projects a net sales growth of 17%-20% for 2026 at constant exchange rates, with core EBITDA margin expected to reach approximately 26% [4]. Market Position - Galderma ranks 11th among global beauty groups with a revenue of $5.207 billion, closing the gap with the 10th place Coty, which is only about $500 million ahead [7]. - The company's growth is attributed to the success of its three main business segments, which complement each other in revenue contribution, profit margins, innovation potential, and resilience [7]. Business Segments - The Injectable Aesthetics segment is the largest revenue source, with net sales of $2.572 billion, showing a year-on-year growth of 11.5% [8]. - The Dermatological Skincare segment generated net sales of $1.449 billion, with a year-on-year increase of 9.3%, driven by strong performances from brands like Cetaphil and Alastin [8]. - The Therapeutic Dermatology segment experienced the fastest growth, with net sales of $1.185 billion, a remarkable year-on-year increase of 50.2%, largely due to the performance of the Nemluvio brand [8]. Strategic Execution in China - China has become a key testing ground for Galderma's strategic execution, with a focus on integrating global products, cross-segment collaboration, and local research to build a comprehensive health management system [9]. - The brand Cetaphil has been a significant driver of growth in China, particularly during promotional events like Double Eleven, outperforming the overall skincare market [9]. Product Innovations - In 2025, Galderma introduced several key products to the Chinese market, including the globally recognized regenerative aesthetic product Sculptra, marking a strategic move into the Chinese regenerative aesthetic market [11]. - The launch of the innovative perioperative skincare brand Alastin further extends the company's offerings from treatment to pre- and post-procedure care, creating a complete "injection + care" loop [11]. Research and Development - Galderma is advancing its R&D investments in China, with a clinical study focusing on the biological impacts of lifestyle and environmental factors on sensitive skin populations [13]. - The company has established a robust R&D network with over 650 personnel across 33 global research bases, emphasizing clinical validation and efficacy in product development [20]. Competitive Landscape - The global beauty industry is witnessing a shift towards medical aesthetics, with major players like L'Oréal and Estée Lauder increasing their focus on this high-growth segment [14][15]. - Galderma's unique vertical integration model allows it to meet diverse consumer needs across different skin conditions and life stages, creating a competitive moat that traditional beauty brands find hard to replicate [21].